



PTO/SB/08A (10-01)  
Approved for use through 10/31/2002 OMB 0651-0031  
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |                          |                   |                        |              |
|---|---|--------------------------|-------------------|------------------------|--------------|
| <b>Substitute for form 1449A/PTO</b><br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(use as many sheets as necessary) |   | <b>Complete if Known</b> |                   |                        |              |
|   |   | Application Number       | 10/077,555        |                        |              |
|   |   | Filing Date              | February 15, 2002 |                        |              |
|   |   | First Named Inventor     | Rong-Fu Wang      |                        |              |
|   |   | Art Unit                 | 1645              |                        |              |
|   |   | Examiner Name            | Not Yet Assigned  |                        |              |
| Sheet   | 1 | of                       | 2                 | Attorney Docket Number | HO-P02373US1 |

| U.S. PATENT DOCUMENTS |                          |  |                                |  |  |
|-----------------------|--------------------------|--|--------------------------------|--|--|
| Examiner<br>Initials* | Cite<br>No. <sup>1</sup> | Document Number                          | Publication Date<br>MM-DD-YYYY | Name of Patentee or Applicant<br>of Cited Document | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear |
|                       |                          | Number-Kind Code <sup>2</sup> (if known) |                                |  |  |
|                       |                          |  |                                |  |  |

| FOREIGN PATENT DOCUMENTS |                          |   |                                |  |  |                |
|--------------------------|--------------------------|---|--------------------------------|--|--|----------------|
| Examiner<br>Initials*    | Cite<br>No. <sup>1</sup> | Foreign Patent Document   | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear | T <sup>3</sup> |
|                          |                          | Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known) |                                |  |  |                |
| SR                       | BA                       | IB-98/46083-A1  | 10/22/1998                     | The Regents of the University of California        |  |                |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See attached Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \* Applicant is to place a check mark here if English language Translation is attached.

| NON PATENT LITERATURE DOCUMENTS |                          |   |  |  |                |
|---------------------------------|--------------------------|---|--|--|----------------|
| Examiner<br>Initials*           | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.                        |  |  | T <sup>2</sup> |
| SR                              | CA                       | Banchereau, Jacques, et al.; Dendritic cells and the control of immunity; Nature, Vol. 392, pp 245 - 252, March 19, 1998  |  |  |                |
|                                 | CB                       | Bellone, Matteo, et al.; Relevance of the Tumor Antigen in the Validation of Three Vaccination Strategies for Melanoma; The Journal of Immunology, 2000, 165:2651 - 2656  |  |  |                |
|                                 | CC                       | Cella, Marina, et al.; Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells; Nature, Vol. 388, pp 782 - 787, August 21, 1997   |  |  |                |
|                                 | CD                       | Celluzzi, Christina M., et al.; Peptide-pulsed Dendritic Cells induce Antigen-specific, CTL-mediated Protective Tumor Immunity; J. Exp. Med., Vol. 183, pp 283 - 287, January 1996  |  |  |                |
|                                 | CE                       | Dallal, Ramsey M., et al.; The dendritic cell and human cancer vaccines; Current Opinion in Immunology 2000, 12:583 - 588   |  |  |                |
|                                 | CF                       | Houghton, Alan N., et al.; Immunity against cancer: lessons learned from melanoma; Current Opinion in Immunology, 2001, 13:134 - 140  |  |  |                |
|                                 | CG                       | Gilboa, Eli; The Makings of a Tumor Rejection Antigen; Immunity, Vol. 11, pp 263 - 270, September 1999  |  |  |                |
|                                 | CH                       | Ludewig, Burkhard, et al.; Role of dendritic cells in the induction and maintenance of autoimmune diseases; Immunological Reviews 1999, Vol. 169:45 - 54  |  |  |                |
|                                 | CI                       | Mehta-Damani, Anita, et al.; Generation of Antigen-specific CD8+ CTLs from Naive Precursors; The Journal of Immunology, 1994, 153: 996 - 1003   |  |  |                |
|                                 | CJ                       | Nestle, Frank O., et al.; Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells; Nature medicine, Vol. 4 (3), pp 328 - 332, March 1998  |  |  |                |
|                                 | CK                       | Overwijk, Willem W., et al.; Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4+ T lymphocytes; Proc. Natl. Acad. Sci. USA (Immunology), Vol. 96, pp 2982 - 2987, March 1999 |  |  |                |

|                       |  |                    |          |
|-----------------------|--|--------------------|----------|
| Examiner<br>Signature |  | Date<br>Considered | 10/18/05 |
|-----------------------|--|--------------------|----------|



Under the Patent Information Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

|   |   |                          |                   |                        |              |
|---|---|--------------------------|-------------------|------------------------|--------------|
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(use as many sheets as necessary) |   | <b>Complete If Known</b> |                   |                        |              |
|   |   | Application Number       | 10/077,555        |                        |              |
|   |   | Filing Date              | February 15, 2002 |                        |              |
|   |   | First Named Inventor     | Rong-Fu Wang      |                        |              |
|   |   | Art Unit                 | 1645              |                        |              |
|   |   | Examiner Name            | Not Yet Assigned  |                        |              |
| Sheet   | 2 | of                       | 2                 | Attorney Docket Number | HO-P02373US1 |

RECEIVED  
JAN 30 2003  
CHICAGO 160012900

|    |    |  |  |
|----|----|--|--|
| SR | CL | Paglia, Paola, et al.; Murine Dendritic Cells Loaded In Vitro with Soluble Protein Prime Cytotoxic T Lymphocytes against Tumor Antigen In Vivo; J. Exp. Med., Vol. 183, pp 317 - 322, January 1996   |  |
|    | CM | Schreurs, Marco W. J., et al.; Dendritic Cells Break Tolerance and Induce Protective Ummunity against a Melanocyte Differentiation Antigen in an Autologous Melanoma Model; Cancer Research, Vol. 60, pp 6995 - 7001, December 15, 2000  |  |
|    | CN | Schuler, G., et al.; Commentary - Dendritic Cells as Adjuvants for Immune-mediated Resistance to Tumors; J. Exp. Med., Vol. 186 (8), pp 1183 - 1187, October 20, 1997  |  |
|    | CO | Thurner, Beatrice, et al.; Vaccination with Mage-3A1 Peptide-pulsed Mature, Monocyte-derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma; J. Exp. Med., Vol. 190 (11), pp 1669 - 1678, December 6, 1999 |  |
|    | CP | Young, James W., et al.; Dendritic Cells as Adjuvants for Class I Major Histocompatibility Complex-restricted Antitumor Immunity; J. Exp. Med., Vol. 183, pp 7 - 11, January 1996  |  |
|    | CQ | Wang, Rong-Fu, et al.; Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells; Nature Biotechnology, Vol. 20, pp 149 - 154, February 2002   |  |
| ✓  | CR | Wang, Rong-Fu, et al.; Human tumor antigens for cancer vaccine development; Immunological Reviews, Vol. 170:85 - 100, 1999   |  |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

|                    |  |                 |          |
|--------------------|--|-----------------|----------|
| Examiner Signature |  | Date Considered | 10/18/05 |
|--------------------|--|-----------------|----------|